---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-271116"
form_type: "8-K"
ticker: "CGON"
cik: "0001991792"
company_name: "CG Oncology, Inc."
filed_at: "2024-12-05T23:59:59+00:00"
generated_at: "2026-05-29T07:29:08.346120+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# CG Oncology reports 74.5% CR rate in Phase 3 BOND-003; median DOR >27 months

## Summary
- 74.5% (82/110) achieved complete response at any time (95% CI 65.4-82.4%).
- Median duration of response not reached but exceeds 27 months; 63.5% probability of response at 12 months.
- No Grade 3+ treatment-related adverse events or deaths; 97.3% completed all treatments.
- Progression-free survival at 12 months: 97.3%; no progression to muscle-invasive cancer.
- Cystectomy-free survival at 12 months: 90.0%; 50% of reinduced patients converted to CR.

## SEC filing metadata
- accession: 0001193125-24-271116
- form_type: 8-K
- ticker: CGON
- cik: 0001991792
- company_name: CG Oncology, Inc.
- filed_at: 2024-12-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1991792/000119312524271116/0001193125-24-271116-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1991792/000119312524271116/d809707d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-271116
- JSON: https://secwatch.observer/filing/0001193125-24-271116.json
- Plain text: https://secwatch.observer/filing/0001193125-24-271116.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.